HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
Authors
Keywords
-
Journal
World Journal of Clinical Cases
Volume 7, Issue 15, Pages 1964-1977
Publisher
Baishideng Publishing Group Inc.
Online
2019-08-06
DOI
10.12998/wjcc.v7.i15.1964
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- HER2 Heterogeneity in Gastroesophageal Cancer Detected by Testing Biopsy and Resection Specimens
- (2018) Ladan Fazlollahi et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
- (2018) Takeru Wakatsuki et al. JOURNAL OF GASTROENTEROLOGY
- Clinicopathological features and endoscopic findings of HER2-positive gastric cancer
- (2018) Yasuhiro Oono et al. SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
- Prognostic implications of HER2 heterogeneity in gastric cancer
- (2018) Shigenobu Motoshima et al. Oncotarget
- Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
- (2018) Josep Tabernero et al. LANCET ONCOLOGY
- Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer
- (2018) Shusuke Yagi et al. Gastric Cancer
- HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology
- (2017) Angela N. Bartley et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-colorin situhybridization
- (2016) Kazuki Kanayama et al. CANCER SCIENCE
- Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1)
- (2016) Sook Ryun Park et al. EUROPEAN JOURNAL OF CANCER
- Japanese gastric cancer treatment guidelines 2014 (ver. 4)
- (2016) Gastric Cancer
- Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology
- (2016) Jaffer A. Ajani et al. Journal of the National Comprehensive Cancer Network
- Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab
- (2015) Hee Jin Lee et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens
- (2015) Sangjeong Ahn et al. Oncotarget
- HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer
- (2014) Hee Jin Lee et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
- (2014) Eric Van Cutsem et al. Gastric Cancer
- Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer
- (2014) Yukinori Kurokawa et al. Gastric Cancer
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
- (2014) Taroh Satoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
- (2014) Luca Gianni et al. LANCET ONCOLOGY
- Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma
- (2014) Hiroshi Yoshida et al. VIRCHOWS ARCHIV
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical significance of intratumoral HER2 heterogeneity in gastric cancer
- (2012) Hee Eun Lee et al. EUROPEAN JOURNAL OF CANCER
- Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance
- (2012) Hyesil Seol et al. MODERN PATHOLOGY
- HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care
- (2011) A. Fabi et al. CLINICAL CANCER RESEARCH
- Japanese classification of gastric carcinoma: 3rd English edition
- (2011) Gastric Cancer
- HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens
- (2010) Hitoshi Tsuda et al. BMC CANCER
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study)
- (2009) W. Koizumi et al. ANNALS OF ONCOLOGY
- Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
- (2009) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More